Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 Years

20260 citationsJournal Articlehybrid Open Access

Authors

Yoshiya Tanaka · University of Occupational and Environmental Health Japan

Akira Kondo · Gilead Sciences (United States)

Hisaaki Isaji · Gilead Sciences (United States)

Katrien Van Beneden · Alfasigma (Italy)

Roger Mutter · Alfasigma (Italy)

Tsutomu Takeuchi · Saitama Medical University

Abstract

Long-term filgotinib treatment was well tolerated at 200 mg and 100 mg in Japanese patients with RA over up to 5 years, confirming previous global analyses.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Spondyloarthritis Studies and Treatments Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Modern Rheumatology

DOI: 10.1093/mr/roag029

Field-Weighted Citation Impact: 0.00